Tighe Reardon - Jan 2, 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Acting Chief Financial Officer, 10%+ Owner
Signature
/s/ Maria Dobek, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/3/2024, 04:52 PM
Previous filing
Nov 15, 2023
Next filing
Jun 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Award $0 +157K $0.00 157K Jan 2, 2024 Common Stock 157K $11.02 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period.